Axcella
Axcella Health Inc., established in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions targeting various biological pathways. The company's pipeline includes AXA1665 for hepatic encephalopathy, AXA1125 and AXA1957 for non-alcoholic steatohepatitis, AXA2678 for muscle atrophy, and AXA4010 for multiple biological pathways.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.